Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS^G12D-mutated non-small-cell lung cancer.

ABSTRACT:

Background

Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRAS^MUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous outcomes, driven by differences in underlying biology shaped by co-mutations. In contrast to KRAS^G12C NSCLC, KRAS^G12D NSCLC is associated with low/never-smoking status and is largely uncharacterized.

Patients and methods

Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1

SUBMITTER: Ricciuti B 

PROVIDER: S-EPMC11006449 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature